CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ADHD
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
Trial Timeline
Dec 29, 2022 → Jun 13, 2023
NCT ID
NCT05631626About CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + Placebo
CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + Placebo is a phase 3 stage product being developed by Cingulate for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT05631626. Target conditions include ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined.
What happened to similar drugs?
10 of 20 similar drugs in ADHD were approved
Approved (10) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05631626 | Phase 3 | Completed |
Competing Products
20 competing products in ADHD